Additionally, we found that GPR176 expression was negatively associated with male sex, T staging, Her-2 positivity, and mutant p53 status of breast cancer, in line with the positive relationship between GPR176 methylation and pathological stage, and immunohistochemical findings. This evidence concerns the gene ERBB2 and breast carcinoma.